List of Excipients in Branded Drug NEURACEQ

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Lantheus Biosciences Ltd	NEURACEQ	florbetaben f 18	54828-001	ALCOHOL	2032-07-14
Lantheus Biosciences Ltd	NEURACEQ	florbetaben f 18	54828-001	ASCORBIC ACID	2032-07-14
Lantheus Biosciences Ltd	NEURACEQ	florbetaben f 18	54828-001	POLYETHYLENE GLYCOL 400	2032-07-14
Lantheus Biosciences Ltd	NEURACEQ	florbetaben f 18	54828-001	SODIUM ASCORBATE	2032-07-14
Lantheus Biosciences Ltd	NEURACEQ	florbetaben f 18	54828-001	WATER	2032-07-14

NEURACEQ Excipient Strategy and Commercial Opportunities

Last updated: August 6, 2026

Neuraceq, or florbetaben F 18 injection, is a short-lived PET radiopharmaceutical used to estimate beta-amyloid neuritic plaque density in the brains of adults evaluated for cognitive impairment. Its excipient strategy is narrow: the formulation must support radiochemical stability, sterility, injectable tolerability, and reliable performance during production, transport, and administration. The strongest commercial opportunities are therefore in sterile excipient supply, antioxidant and radiolysis-control systems, automated dispensing, decentralized manufacturing, and quality-control services rather than in conventional reformulation.

What is Neuraceq and how is it formulated?

Neuraceq is an intravenous positron emission tomography agent containing florbetaben F 18. The fluorine-18 isotope has a physical half-life of approximately 110 minutes, which imposes strict limits on formulation, release testing, transportation, and inventory management.[1]

The FDA-approved product is supplied as a sterile, clear, colorless injectable solution. The labeled excipient system includes ethanol and sodium ascorbate in water for injection.[1] These components support the operational requirements of a radiopharmaceutical:

Formulation component	Primary technical function	Commercial relevance
Florbetaben F 18	Active PET imaging agent	Radioactive drug substance with rapid decay
Ethanol	Co-solvent and potential radiolysis-control component	Sterile pharmaceutical-grade supply and validated container compatibility
Sodium ascorbate	Antioxidant and formulation stabilizer	Low-endotoxin, sterile antioxidant supply
Water for injection	Injectable vehicle	Compendial sterile water supply

Neuraceq is administered as an intravenous bolus. The labeled adult dose is 300 MBq, with imaging generally performed approximately 90 minutes after injection.[1] The formulation must remain suitable from final production through administration despite radioactive decay and exposure to radiolytic degradation products.

What excipients protect Neuraceq stability?

The most important excipient strategy is the combination of a water-based injectable vehicle with an alcohol co-solvent and an antioxidant. Fluorine-18 radiopharmaceuticals can undergo radiolysis, producing reactive species that may reduce radiochemical purity or generate degradants. Sodium ascorbate is commercially relevant because antioxidant control is central to maintaining product quality during the limited period between synthesis and patient administration.

Ethanol has several potential formulation functions:

• It can improve solubilization of lipophilic drug-related species.
• It can influence radiolysis and reactive oxygen chemistry.
• It can affect extraction, residual-solvent control, and container compatibility.
• It must remain within validated limits for intravenous administration.

The commercial value of these excipients is tied to performance under radiopharmaceutical conditions. A conventional excipient supplier may not satisfy requirements for sterile filtration, low bioburden, endotoxin control, extractables and leachables, and batch-to-batch impurity consistency.

What formulation properties are most important?

For Neuraceq and comparable fluorine-18 products, the critical quality attributes include:

1. Radiochemical identity and purity.
2. Chemical purity.
3. Radioactivity concentration and total activity.
4. pH.
5. Sterility and bacterial endotoxins.
6. Appearance and particulate control.
7. Residual solvent levels.
8. Stability during the product's short distribution and use window.

Because the product is radioactive and short-lived, conventional long-term stability programs have less commercial value than rapid release testing and process robustness. Formulation suppliers that reduce synthesis failures or improve release predictability can have greater economic impact than suppliers offering a marginally longer shelf life.

What commercial opportunities exist for Neuraceq excipients?

The largest opportunities are in specialized pharmaceutical-grade inputs and manufacturing systems.

Sterile sodium ascorbate supply

Sodium ascorbate is a relatively familiar pharmaceutical ingredient, but radiopharmaceutical use creates stricter operational requirements. Suppliers can differentiate through:

• Sterile or low-bioburden presentations.
• Low endotoxin specifications.
• Tight control of trace metals and peroxide-forming impurities.
• Small-volume packaging suitable for radiopharmaceutical production.
• Documentation compatible with FDA chemistry, manufacturing, and controls submissions.
• Regional supply continuity for nuclear pharmacies and PET manufacturing sites.

A supplier that can provide validated sterile antioxidant material in radiopharmaceutical-scale quantities may capture business even where the underlying molecule is off patent.

Pharmaceutical-grade ethanol

Ethanol supply is less technically differentiated than sodium ascorbate, but quality and logistics remain important. Opportunities include:

• Sterile-filterable ethanol systems.
• Qualified container-closure combinations.
• Low levels of aldehydes, peroxides, and nonvolatile residues.
• Supply in formats compatible with automated synthesis modules.
• Documentation for multi-site manufacturing networks.

The commercial risk is substitution. Ethanol is widely available, so a supplier must compete on qualification support, regulatory documentation, delivery reliability, and compatibility with validated production processes.

Radiolysis-control systems

A stronger opportunity lies in integrated formulation and process controls rather than in a single excipient. Suppliers may offer:

• Antioxidant optimization.
• Oxygen-control procedures.
• Nitrogen or inert-gas overlays.
• Light-protection systems.
• Low-adsorption tubing and vials.
• Validated hold-time studies.
• Automated correction of activity concentration.

These solutions can reduce out-of-specification batches and improve usable production yield. They may be protected through process patents, device patents, or trade secrets even when the excipients themselves are not patentable in a commercially meaningful way.

What patents protect Neuraceq and its formulation?

Neuraceq's commercial protection is primarily associated with the florbetaben molecule, radiolabeled imaging methods, diagnostic use, manufacturing processes, and regulatory exclusivity. The public FDA prescribing information does not identify a formulation patent number or an excipient-specific patent claim for the ethanol and sodium ascorbate vehicle.[1]

A conventional excipient combination is difficult to protect broadly unless it produces an unexpected technical result. Potentially protectable subject matter could include:

• A defined florbetaben F 18 formulation with specified antioxidant concentration.
• A radiochemical stabilization method.
• A process that improves radiochemical purity during synthesis or storage.
• A container-closure system that reduces adsorption or radiolytic degradation.
• A dispensing method that controls residual activity and dose accuracy.
• A PET imaging method linked to a defined patient population.

The strongest freedom-to-operate risks are therefore more likely to arise from active-agent, synthesis, imaging-method, or device patents than from ordinary use of ethanol or sodium ascorbate.

What is the FDA regulatory status of Neuraceq?

The FDA approved Neuraceq in 2014 as a diagnostic radiopharmaceutical for PET imaging of the brain.[1] The label limits its use to estimating beta-amyloid neuritic plaque density. A positive scan does not independently establish a diagnosis of Alzheimer disease or another cognitive disorder; clinical assessment remains necessary.[1]

Neuraceq is regulated as a drug and radiopharmaceutical. Manufacturing must comply with applicable drug cGMP requirements, sterile-product controls, radioactive-material controls, and state or federal nuclear-regulatory requirements. The short half-life creates a practical need for geographically distributed production or rapid shipment from qualified PET manufacturing centers.

What is the Orange Book status of Neuraceq?

The Orange Book is relevant to small-molecule prescription drugs, but its listed-patent record must be evaluated separately from the product label. The FDA label does not provide a confirmed excipient-patent listing for Neuraceq.[1] No business decision should assume that the ethanol or sodium ascorbate formulation is protected by an Orange Book-listed patent.

For generic or follow-on entry, the key review points are:

Issue	Neuraceq relevance
Listed drug	Florbetaben F 18 injection
Dosage form	Intravenous injection
Active ingredient	Florbetaben F 18
Excipients	Ethanol, sodium ascorbate, water for injection
Regulatory pathway	Abbreviated or full application strategy depends on product and legal framework
Patent risk	More likely active-agent, process, diagnostic-method, or device-related than excipient-related
Bioequivalence	Conventional systemic bioequivalence concepts may not fully capture PET imaging performance
Manufacturing challenge	Radioactive synthesis, sterile processing, release testing, and time-sensitive distribution

A follow-on manufacturer would need to address radiochemical equivalence, chemical impurities, sterility, endotoxins, dose calibration, imaging performance, and labeling. A formulation that is compositionally similar but operationally unstable would have limited commercial value.

When does Neuraceq lose exclusivity?

Neuraceq's commercial exclusivity depends on the underlying patent portfolio, regulatory exclusivity, and the enforceability of any remaining claims. The FDA approval date alone does not establish the final generic-entry date. Patent expiration must be determined from issued patent records, terminal disclaimers, patent-term adjustments, patent-term extensions, and litigation outcomes.

The practical exclusivity picture has several layers:

• Regulatory exclusivity attached to the original FDA approval.
• Composition-of-matter protection for florbetaben or related chemical entities.
• Radiolabeling and precursor-manufacturing patents.
• Diagnostic method-of-use patents.
• Formulation or stability patents.
• Trade secrets covering synthesis, purification, and release testing.
• Distribution and production know-how.

For commercial planning, excipient suppliers should assume that basic formulation ingredients will not retain meaningful exclusivity after active-agent patents expire. The defensible value is more likely to reside in qualification, process integration, manufacturing know-how, and supply reliability.

Are there Paragraph IV challenges to Neuraceq?

A Paragraph IV challenge would require a generic applicant to certify that a listed patent is invalid, unenforceable, or will not be infringed. Public product-label materials do not establish a current Paragraph IV litigation position for Neuraceq.[1]

The economic case for a Paragraph IV filing is narrower than for a high-volume chronic medicine. Florbetaben F 18 is a specialized diagnostic product with:

• A short isotope half-life.
• Significant site qualification requirements.
• Regional manufacturing constraints.
• Limited inventory flexibility.
• High dependence on PET imaging capacity.
• Potentially modest unit volume relative to blockbuster therapeutics.

A successful entrant would need more than legal clearance. It would need a reliable fluorine-18 supply, qualified synthesis equipment, sterile production, validated release testing, and a commercial network of imaging centers.

How does Neuraceq compare with Amyvid and Vizamyl?

Neuraceq competes with other amyloid PET agents, principally Amyvid, which contains florbetapir F 18, and Vizamyl, which contains flutemetamol F 18. All three products face similar isotope, sterility, logistics, and reimbursement constraints.

Product	Active radiotracer	Commercial comparison
Neuraceq	Florbetaben F 18	Formulation opportunity centered on antioxidant stability and sterile supply
Amyvid	Florbetapir F 18	Competes for amyloid PET sites and radiopharmaceutical distribution
Vizamyl	Flutemetamol F 18	Competes on imaging availability, reader familiarity, and manufacturing reach

Excipient differentiation is unlikely to determine market share by itself. Availability, payer coverage, radiochemistry yield, image interpretation, manufacturing radius, and scanner access are more important commercial variables.

What manufacturing and IP barriers affect Neuraceq?

The principal barriers are operational rather than excipient-specific.

Fluorine-18 supply

Fluorine-18 must be produced near the point of use or transported rapidly. Cyclotron access, target processing, precursor availability, and scheduling affect product reliability.

Automated synthesis

Validated synthesis modules and software-controlled processes can be difficult to replicate because they incorporate proprietary parameters, equipment configurations, and process knowledge.

Sterile production

A sterile radiopharmaceutical requires aseptic processing, environmental control, rapid filtration, validated vials, and release testing under severe time constraints.

Analytical release

The manufacturer must confirm identity, purity, activity, pH, sterility-related requirements, and other specifications before administration. Faster and more reliable analytical workflows create a meaningful commercial advantage.

Geographic coverage

A manufacturer may have an approved product but lack the regional production network required to serve distant imaging centers. Geographic manufacturing coverage is therefore part of the effective competitive moat.

Which licensing opportunities exist around Neuraceq?

The most plausible licensing opportunities are not simple excipient licenses. They are integrated arrangements involving:

• Florbetaben precursor supply.
• Automated radiochemistry platforms.
• Sterile vial and container systems.
• Antioxidant-stabilized formulation technology.
• PET manufacturing software.
• Regional production rights.
• Contract manufacturing for hospital or commercial PET networks.
• Quality-control and release-testing platforms.

A formulation patent covering sodium ascorbate or ethanol alone would likely have limited value. A license combining formulation know-how, validated manufacturing parameters, container compatibility, and regulatory support would have stronger commercial utility.

What revenue exposure does Neuraceq create for excipient suppliers?

Neuraceq is not a high-volume excipient market. The drug's radioactivity limits batch size, shelf life, and inventory. Revenue exposure for a supplier is therefore likely to be modest on a per-dose basis but strategically valuable if the supplier supports several PET radiopharmaceuticals.

The strongest portfolio strategy is to sell the same sterile antioxidant, solvent, container, or process-control platform into:

• Florbetaben F 18 products.
• Florbetapir F 18 products.
• Flutemetamol F 18 products.
• Tau PET agents.
• Oncology PET tracers.
• Cardiac and infection imaging radiopharmaceuticals.

Cross-product qualification can reduce customer switching and spread development costs over a larger radiopharmaceutical portfolio.

Key Takeaways

• Neuraceq is a florbetaben F 18 PET injection used for beta-amyloid plaque imaging.
• Its labeled excipients are ethanol, sodium ascorbate, and water for injection.
• The main technical objective is radiochemical and chemical stability during a short manufacturing-to-administration window.
• Basic excipient composition is unlikely to provide durable exclusivity.
• The strongest commercial opportunities are sterile sodium ascorbate, qualified ethanol, container systems, radiolysis controls, automated dispensing, and rapid release testing.
• Patent risk is more likely to arise from florbetaben, radiolabeling, synthesis, imaging methods, or manufacturing processes than from the excipient vehicle.
• Geographic production capacity and fluorine-18 logistics are major barriers to follow-on entry.
• Excipient suppliers should pursue platform licensing across multiple fluorine-18 radiopharmaceuticals rather than rely on Neuraceq alone.

FAQs

Can Neuraceq use a different antioxidant instead of sodium ascorbate?

A substitute antioxidant would require formulation development, comparative stability data, radiochemical-purity testing, sterile-process validation, and regulatory approval. Direct substitution is not a routine commercial change.

Is ethanol in Neuraceq a patentable formulation feature?

Ethanol alone is unlikely to support broad protection. Patent value would depend on a specific concentration range, combination, process, or demonstrated stability benefit.

What is the biggest generic-entry barrier for Neuraceq?

The largest barrier is the integrated manufacturing system: cyclotron access, fluorine-18 handling, sterile synthesis, rapid release testing, and regional distribution.

Can Neuraceq be manufactured in a central facility and shipped nationally?

The short fluorine-18 half-life makes national distribution difficult. Commercial feasibility depends on production timing, transportation distance, activity calibration, and local PET demand.

Are Neuraceq excipients useful for other radiopharmaceuticals?

Yes. Sterile antioxidants, qualified solvents, low-adsorption containers, and radiolysis-control processes may be adaptable to other fluorine-18 PET products, subject to product-specific validation.

References

1. U.S. Food and Drug Administration. (2014). Neuraceq (florbetaben F 18 injection) prescribing information. FDA.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

3. U.S. Food and Drug Administration. (2023). PET drugs: Current good manufacturing practice; small entity compliance guide. FDA.

4. U.S. Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. USP.

5. European Medicines Agency. (2014). Neuraceq: EPAR product information. EMA.